<DOC>
	<DOCNO>NCT01226576</DOCNO>
	<brief_summary>The hypothesis feasibility study focal treatment ExAblate MRgFUS potential safe effective non-invasive treatment low intermediate risk , organ-confined prostate cancer involve low incidence morbidity . The study hypothesis test measure treatment-related safety initial effectiveness parameter ExAblate MRgFUS treat patient , describe . Based result study , InSightec initiate large study effort approve low risk , organ-confined prostate cancer indication ExAblate MRgFUS device .</brief_summary>
	<brief_title>Focal MR-Guided Focused Ultrasound Treatment Localized Low-Intermediate Risk Prostate Cancer : Feasibility Study</brief_title>
	<detailed_description>Objective feasibility trial ass safety initial effectiveness ExAblate MRgFUS treatment low intermediate risk , localize ( organ confine ) prostate cancer tumor . ExAblate treatment implement focal tumor-selective therapy , direct pre-defined volume ( ) /sector ( ) prostate , ( identify cancerous map biopsy without multi-parametric MRI ) , rather whole gland hemi-ablation treatment . Safety : evaluate incidence severity adverse event associate ExAblate 's MRgFUS focal treatment low risk organ confine prostate cancer . The risk ExAblate treatment-related incontinence impotence also assess study . Effectiveness : determine tumor control effect ExAblate 's MRgFUS focal treatment low risk organ-confined prostate cancer ( confirm TRUS-guided Transperineal Mapping Biopsy result ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Patient age 50 75 year , inclusive . 2 . Biopsy confirm adenocarcinoma prostate , perform 6 month prior schedule treatment . 3 . Patient lowintermediate risk , earlystage organconfined prostate cancer ( cT1c cT2a , N0 , M0 ) , diagnose TRUS guide transperineal biopsy ( TPBx ) voluntarily choose MRgFUS noninvasive treatment , may currently watchful wait active surveillance need imminent radical therapy . 4 . Patient PSA less equal 10 ng/mL 5 . Gleason score 6 7 ( 5 grade ) , base TRUS guide Transperineal Mapping Biopsy , define protocol . 6 . Up two ( 2 ) cancerous lesion may identify prostate ; tumor 10 mm maximal linear dimension ; tumor comply maximal 7 Gleason score requirement . 7 . Positive TRUSguided transperineal biopsy ( TPBx ) core , detect maximum four ( 4 ) sector , ( 2 cancerous focus ) 16 sector ( 12 sector prostates volume &lt; 20 cc ) 8 . Low grade tumor may may visible multiparametric MRI . Thus , case MRIvisible tumor , tumor capsular contact le 5 mm , axial image . 9 . No definite evidence extracapsular extension seminal invasion MRI 10 . Patient eligible epidural anesthesia , general anesthesia ( case complication , require intervention ) . 11 . Patient willing able give consent attend study visit define protocol 12 . Prostate gland volume great 70 cc , volumetrically measure . 1 . ASA status &gt; 2 2 . Contraindications MRI 2.1 . Claustrophobia 2.2 . Implanted ferromagnetic material foreign object 2.3 . Known intolerance MRI contrast agent ( e.g . Gadolinium Magnevist ) 2.4 . Known contraindication utilization MRI contrast agent 3 . Severely abnormal coagulation ( INR &gt; 1.5 ) 4 . Patient unstable cardiac status include : 4.1 . Unstable angina pectoris medication 4.2 . Documented myocardial infarction within 40 day prior enrolment 4.3 . Congestive heart failure NYHA class IV 4.4 . Unstable arrhythmia status , already antiarrhythmic drug 5 . Severe hypertension ( diastolic BP &gt; 100 medication ) 6 . Severe cerebrovascular disease ( multiple CVA CVA within 6 month ) 7 . History orchiectomy , PCaspecific chemotherapy , cryotherapy , Photodynamic therapy radical prostatectomy treatment prostate cancer ; prior radiation therapy pelvis prostate cancer malignancy . 8 . Patient medication affect PSA last 3 month prior MRgFUS treatment ( Androgen Deprivation Treatment ; alpha reductase inhibitor ) 9 . Individuals able willing tolerate require prolonged stationary supine position treatment ( approximately 3 hr . ) 10 . Any rectal pathology , anomaly previous treatment , change acoustic property rectal wall prevent safe probe insertion ( e.g. , fistula , stenosis , fibrosis ) . 11 . Any spinal pathology prevent safe administration epidural anesthesia 12 . Identified calcification 2 mm large diameter neighbor rectal wall ( distance le 5 mm ) interfere acoustic beam path . 13 . Lower limb musculoskeletal fixed deformity . 14 . Prostate multiple cystic lesion . 15 . Evidence seminal vesicle/lymph node involvement cancer . 16 . Subjects distance le 2mm margin tumor prostate capsule 17 . Bladder cancer 18 . Patient TURP procedure 19 . Urethral stricture/bladder neck contracture 20 . Patient baseline symptom incontinence define urine leak follow circumstance : 20.1 . Before patient get toilet 20.2 . When cough sneeze 20.3 . While asleep 20.4 . While physically active/exercising 20.5 . After finish urinate dressed 20.6 . Leaking obvious reason 21 . Patient baseline impotence score 17 IIEF5 ( SHIM ) questionnaire 22 . Active UTI 23 . Prostatitis NIH category I , II III 24 . Implant near ( &lt; 1 cm ) prostate 25 . Interest future fertility 26 . Current participation another clinical investigation medical device drug participate study within 30 day prior study enrollment</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>MRgFUS</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Low-Intermediate Risk Prostate Cancer</keyword>
	<keyword>Localized Prostate Cancer</keyword>
	<keyword>InSightec</keyword>
	<keyword>ExAblate</keyword>
</DOC>